公开(公告)号：US20180153861A1

公开(公告)日：2018-06-07

申请号：US15831545

申请日：2017-12-05

Applicant: NOVARTIS AG

Inventor： Yoshie ARAI ,  Margaret Elizabeth Brosseau ,  Jessie Gu ,  Tomoko Hayashi ,  Hironobu Mitani ,  Muneto Mogi ,  Kazuhiko Nonomura ,  Ken Yamada

IPC: A61K31/421 ,  A61K31/55 ,  A61K31/41 ,  A61K31/506 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/44 ,  A61K31/505 ,  A61K45/06 ,  A61K31/5377

CPC classification number: A61K31/421 ,  A61K31/41 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06

Abstract: The present invention provides a compound of Formula I for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein R1, X1, R7, R5, C, L and p are defined herein. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride levels.

公开(公告)号：US20140134262A1

公开(公告)日：2014-05-15

申请号：US14128877

申请日：2012-07-06

Applicant: NOVARTIS AG

Inventor： Yoshie Arai ,  Margaret Elizabeth Brousseau ,  Jessie Gu ,  Tomoko Hayashi ,  Hironobu Mitani ,  Muneto Mogi ,  Kazuhiko Nonomura ,  Ken Yamada

IPC: A61K31/5377 ,  A61K31/4709 ,  A61K31/506 ,  A61K45/06 ,  A61K31/44 ,  A61K31/55 ,  A61K31/421 ,  A61K31/444 ,  A61K31/4439

CPC classification number: A61K31/421 ,  A61K31/41 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06

Abstract: The present invention provides a compound of Formula I: for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein R1, X1, R7, R5, C, L and p are defined herein. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride levels.

Abstract translation: 本发明提供式I化合物：用于治疗，改善和/或预防与甘油三酯水平高的受试者中CETP活性相关的疾病和病症，例如动脉粥样硬化和血脂异常; 其中R1，X1，R7，R5，C，L和p在本文中定义。 本发明还提供了用于治疗，改善和/或预防与甘油三酯水平高的受试者中CETP活性如动脉粥样硬化和血脂异常相关的疾病和病症的药理活性剂的组合。

公开(公告)号：US20210186950A1

公开(公告)日：2021-06-24

申请号：US17055468

申请日：2019-05-28

Applicant: NOVARTIS AG

Inventor： Jessie Gu ,  Marcos Pedrosa ,  Rowan Stringer

IPC: A61K31/46 ,  A61K31/4178

Abstract: The invention provides a pharmaceutical combination comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo [3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid or a stereoisomer, enantiomer, pharmaceutically acceptable salt, prodrug, ester thereof or amino acid conjugate thereof; and cenicriviroc or a pharmaceutically acceptable salt, solvate, prodrug or ester thereof; for use in treating or preventing a liver disease or disorder.

公开(公告)号：US20150320725A1

公开(公告)日：2015-11-12

申请号：US14709607

申请日：2015-05-12

Applicant: Novartis AG

Inventor： Jessie Gu

IPC: A61K31/4184

CPC classification number: A61K31/4184 ,  A61K31/416 ,  C07D235/08

Abstract: The use of a MEK inhibitor compound of Formula (I), as defined herein, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of Noonan Syndrome, a method of treating a warm-blooded animal, especially a human, having Noonan Syndrome, comprising administering to said animal a therapeutically effective amount of a MEK inhibitor compound of Formula (I), as defined herein, or a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition and a commercial package comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a package insert or other labeling including directions for treating Noonan Syndrome.

Abstract translation: 使用如本文所定义的式（I）的MEK抑制剂化合物或其药学上可接受的盐在制备用于治疗Noonan综合征的药物中的用途，一种治疗温血动物，特别是人的方法， 包括向所述动物施用治疗有效量的如本文所定义的式（I）的MEK抑制剂化合物或其药学上可接受的盐，以及药物组合物和商业包装，其包含式（I）化合物 I）或其药学上可接受的盐，以及包装插页或包括治疗Noonan综合征指示的其他标签。